MY105479A - Aromatase inhibitors. - Google Patents

Aromatase inhibitors.

Info

Publication number
MY105479A
MY105479A MYPI91000193A MYPI19910193A MY105479A MY 105479 A MY105479 A MY 105479A MY PI91000193 A MYPI91000193 A MY PI91000193A MY PI19910193 A MYPI19910193 A MY PI19910193A MY 105479 A MY105479 A MY 105479A
Authority
MY
Malaysia
Prior art keywords
aromatase inhibitors
compounds
aromatase
androstanedione
estrogen
Prior art date
Application number
MYPI91000193A
Other languages
English (en)
Inventor
Yves Merand
Fernand Labrie
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of MY105479A publication Critical patent/MY105479A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI91000193A 1990-02-08 1991-02-08 Aromatase inhibitors. MY105479A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/477,024 US5227375A (en) 1990-02-08 1990-02-08 Aromatase inhibitors

Publications (1)

Publication Number Publication Date
MY105479A true MY105479A (en) 1994-10-31

Family

ID=23894189

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI91000193A MY105479A (en) 1990-02-08 1991-02-08 Aromatase inhibitors.

Country Status (10)

Country Link
US (1) US5227375A (enExample)
AU (1) AU7150991A (enExample)
GR (1) GR910100067A (enExample)
IE (1) IE65269B1 (enExample)
IL (1) IL97122A (enExample)
MY (1) MY105479A (enExample)
NZ (1) NZ236966A (enExample)
TW (1) TW221418B (enExample)
WO (1) WO1991012206A2 (enExample)
ZA (1) ZA91604B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017489A1 (fr) * 1991-03-28 1992-10-15 Teikoku Hormone Mfg. Co., Ltd. Nouveau derive oxa- ou azasteroide
DE69324595T2 (de) * 1992-09-30 1999-08-19 Teikoku Hormone Mfg. Co. 7-substituierte oxa-steroid verbindung
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
MXPA00008868A (es) 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
EP1219631A4 (en) * 1999-08-23 2003-03-19 Chugai Pharmaceutical Co Ltd ANTIANDROGEN ACTIVE SUBSTANCES
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
TW200401781A (en) * 2002-03-22 2004-02-01 Pharmacia Corp C-17 spirolactonization and 6, 7 oxidation of steroids
RU2004131523A (ru) * 2002-03-22 2005-06-10 Фармация Корпорейшн (Us) С-17-спиролактонизация и 6,7-окисление стероидов
PL376896A1 (pl) * 2002-11-07 2006-01-09 Pharmacia & Upjohn Company Llc Sposoby wytwarzania 5-androstenów podstawionych w pozycji C-7
EP1709062B9 (en) 2004-01-16 2013-02-13 Cedarburg Pharmaceuticals, Inc. Exemestane and its intermediates and methods of making the same
BR112012029392A2 (pt) * 2010-05-20 2017-07-11 Univ Saskatchewan uso d einibidores de aromatase para a sincronização da ovulação, indução da superovulação ou ovulação dupla e melhora da geminação e fertilidade em um mamífero
US10004723B2 (en) 2013-04-19 2018-06-26 University Of Saskatchewan Aromatase inhibitor-releasing intravaginal device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125071C (enExample) * 1963-12-24
US3380886A (en) * 1965-04-07 1968-04-30 Upjohn Co 7alpha-methyl-3beta-hydroxy-5-androstenes
US3591607A (en) * 1966-04-19 1971-07-06 Hoffmann La Roche Retrosteroid a-ring formation
US3766213A (en) * 1966-04-19 1973-10-16 Hoffmann La Roche Retrosteroid a ring formation
US3485828A (en) * 1967-04-10 1969-12-23 Syntex Corp 6,7-ethylene and 6,7-substituted ethylene derivatives of the pregnane series
US3952018A (en) * 1972-01-14 1976-04-20 Hoffmann-La Roche Inc. 15-Oxasteroids
DE2558088C2 (de) * 1975-12-19 1985-05-30 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 4-Androsten-3,17-dion-Derivaten
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4451404A (en) * 1983-02-09 1984-05-29 The Upjohn Company 16β-Methyl steroid process
US4596796A (en) * 1983-09-12 1986-06-24 Sumitomo Chemical Company, Limited Dithiolphosphoric acid ester as a soil pesticide
DE3612632A1 (de) * 1986-04-11 1987-10-22 Schering Ag Verfahren zur herstellung von 7(alpha)-propylsteroiden
GB8617107D0 (en) * 1986-07-14 1986-08-20 Erba Farmitalia 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives
GB8622330D0 (en) * 1986-09-17 1986-10-22 Erba Farmitalia 4-substituted 6-alkylidenandrostene-3,17-dione derivatives

Also Published As

Publication number Publication date
WO1991012206A2 (en) 1991-08-22
ZA91604B (en) 1992-09-30
IL97122A (en) 1996-06-18
WO1991012206A3 (en) 1991-11-28
NZ236966A (en) 1993-11-25
AU7150991A (en) 1991-09-03
TW221418B (enExample) 1994-03-01
US5227375A (en) 1993-07-13
IE910263A1 (en) 1991-08-14
IL97122A0 (en) 1992-05-25
IE65269B1 (en) 1995-10-18
GR910100067A (el) 1992-06-30

Similar Documents

Publication Publication Date Title
MY105479A (en) Aromatase inhibitors.
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
BG105721A (en) Azabicycloalkanes as ccr5 modulators
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
GB2303850B (en) Metalloproteinase inhibitors
GEP20033094B (en) Steroid Sulphatase Inhibitors
IL108007A (en) USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
IL94990A0 (en) Pharmaceutical compositions for the prophylaxis and/or treatment of prostatic diseases
BG106155A (en) Novel derivatives and analogues of galanthamin
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
DK0823903T3 (da) Heterocykliske biarylforbindelser, farmaceutiske præparater og kosmetiske sammensætninger, der indeholder dem, og anvendelser
IL127044A (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenertive diseases
PT1206444E (pt) Compostos que inibem a actividade da triptase
IT1247528B (it) Composto ad attivita' terapeutica,sua preparazione e composizioni farmaceutiche che lo contengono
NO20021625L (no) Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog
BG105342A (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
ATE313332T1 (de) Chaperonin 10 und beta-interferon therapie für multiple sklerose
MX9303574A (es) Compuestos heterociclicos que son inhibidores de la enzima aromatasa, proceso para su preparacion ycomposiciones farmaceuticas que los contienen.
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DK0675895T3 (da) Etoposidderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemiddel og anvendelse deraf til fremstilling af et lægemiddel til anticancerbehandling
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater